Shingles Vaccine and Dementia: What the Evidence Means for You
A birthday rule. An unexpected brain-health clue.
A shingles shot and your memory seem like an unlikely pair. Yet a birthday rule in Wales brought them together. Here is the story behind the research, followed by answers to the questions that matter when you are deciding what to do.
Dr. Shailesh Male, MD
Board-certified neurologist. NeuroClarified explains complex neurological conditions and treatments in clear, clinically grounded language.
Medically reviewed: Sept 28, 2026
Key takeaways
- Shingles vaccination has produced promising dementia findings, but Shingrix is not proven to prevent dementia.
- The established reason to get vaccinated is protection against shingles and its complications.
- Check your age, immune health and vaccination record with your clinician or pharmacist before deciding whether you are due.
What could one week possibly change?
Picture two neighbors born a week apart. They are nearly the same age, but one can get a shingles shot through a public program and the other cannot. Years later, that small birthday difference becomes a clue about dementia.
That is the surprising starting point of this research. It also explains why the findings deserve more attention than a headline alone can give them.
In Wales, the 2013 vaccination program created an unusual comparison. Near its September 2, 1933 cutoff, older adults born just one week apart had sharply different access to the older live shingles vaccine. Uptake rose from almost zero on the too-old side to nearly half on the eligible side.
Why does that matter? People who choose vaccination may also go for more checkups. If they stay healthier, which deserves the credit? The birthday rule gave researchers a fairer comparison: access changed sharply between people of almost the same age. It was still not a randomized trial.
So what did they find?
Researchers estimated that vaccination reduced new dementia diagnoses over seven years by about 3.5 per 100 people, equivalent to about a 20% relative reduction. Those are two ways of describing the same finding—not two separate benefits. The estimate was uncertain: its 95% confidence interval extended from 0.6 to 7.1 fewer diagnoses per 100.
Checks found no clear effect on other common diseases or increased uptake of other preventive care, and no other Welsh program used that same cutoff. Those findings strengthen the interpretation without eliminating every alternative explanation. Eyting and colleagues, Nature, 2025.
Did the clue hold up elsewhere?
Australia offered another birthday cutoff. The same Stanford-led research group found fewer new dementia diagnoses among people just eligible for its older live vaccine program. This was an effect of eligibility; it should not be treated as an identical estimate of receiving a vaccine. A different population adds evidence, but it is not replication by an independent research team. Pomirchy and colleagues, JAMA, 2025.
But is that the vaccine I would get today?
The United States now uses the non-live vaccine Shingrix. A US records study found it was associated with more time without a dementia diagnosis than the older live vaccine. Differences between the groups could still contribute to that association. Taquet and colleagues, Nature Medicine, 2024.
The vaccine studies have not established the mechanism. The important practical distinction is between a promising dementia finding and an established reason to vaccinate.
The reason to act does not depend on the dementia headline
About one in three Americans develops shingles during their lifetime. Shingrix was more than 90% effective against shingles in trials involving adults 50 and older with healthy immune systems. That figure is for shingles, not dementia.
A useful next step is to bring your vaccination record to your clinician or pharmacist and ask whether you are due. You do not have to settle the dementia debate first.
Questions you may still be asking
Who should get Shingrix, and how many doses are needed?
CDC recommends two doses for adults 50 and older, and for adults 19 and older whose immune systems are weakened by disease or treatment. For most people, the doses are two to six months apart. Some immunocompromised adults may need a shorter interval; ask about timing around your treatment. CDC guidance.
I have already had shingles—or the old vaccine. Do I still need Shingrix?
Having had shingles or Zostavax does not remove the recommendation for Shingrix. Your clinician or pharmacist can check what you have received and when. If you have shingles now, wait until it resolves. CDC guidance.
Does this mean Shingrix prevents Alzheimer’s disease?
The study’s main dementia outcome included several diagnoses, including Alzheimer’s and vascular dementia. An overall dementia result is not proof that Shingrix prevents Alzheimer’s specifically—or that its apparent benefit operates only through blood vessels. Taquet and colleagues, Nature Medicine, 2024.
Could the vaccine help someone who already has dementia?
The team also examined Welsh residents who already had dementia. Over nine years, eligible people had fewer deaths recorded as due to dementia. That raises a question about disease progression. Death certificates do not show that memory declined more slowly, and the finding does not establish a dementia treatment. Xie and colleagues, Cell, 2025.
Should I get an extra dose to protect my memory?
No additional dose is recommended on the basis of these dementia findings. Ask whether you are due under the usual vaccination recommendations; the research does not establish an extra-dose strategy for brain protection. CDC guidance.
What about side effects and Guillain-Barré syndrome?
Soreness, tiredness and muscle aches are common and usually settle within a few days. The FDA label also describes a rare Guillain-Barré syndrome signal: one study estimated 3 additional cases per million doses; another estimated 7 additional cases per million doses. Both concern adults 65 and older during the 42 days after vaccination. These are separate estimates of excess cases, not the total incidence of the condition.
Discuss previous Guillain-Barré syndrome or serious vaccine reactions with your clinician. A severe allergic reaction to a previous dose or an ingredient is a contraindication. Seek emergency care for symptoms of a severe allergic reaction, such as difficulty breathing or swelling of the face or throat. FDA Shingrix prescribing information.
Sources and disclosure
The linked papers and official guidance support the sections above. This article draws on NeuroClarified’s V010 video and adapts its explanation for readers.
Dr. Male reports no relationships to disclose for this topic. The companion video uses an AI avatar and AI-assisted illustrations. The number grid is an explanatory graphic, not individual patient records. This article provides general education and does not replace advice from your own clinician.